Sang Uk Lee

Sang Uk Lee

Auto-generated profile, based on publicly available information

Sang Uk Lee

Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in The Korean Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
HPHyun Joon Park
Hyun Joon Park
GCGil-Soon Choi
Gil-Soon Choi
MJMinjung Jung
Minjung Jung
SLSang Uk Lee
Sang Uk Lee
Hyun Joon Park, Gil-Soon Choi, Minjung Jung and Sang Uk Lee. Korean J Gastroenterol 2021;77:39-44. https://doi.org/10.4166/kjg.2020.152

30 June 2025 in Kosin Medical Journal
Verified
Journal Article
Open access
BKBangju Kim
Bangju Kim
HPHyun Joon Park
Hyun Joon Park
SLSang Uk Lee
Sang Uk Lee
KSKwang Il Seo
Kwang Il Seo
JLJung Wook Lee
Jung Wook Lee
JNJun Yeb Nam
Jun Yeb Nam
A combination of atezolizumab and bevacizumab is currently recommended for treating unresectable advanced-stage hepatocellular carcinoma (HCC), as it has demonstrated superior overall survival and progression-free survival compared to sorafenib. However, concerns have been raised regarding serious adverse events associated with bevacizumab, such as gastrointestinal perforation, fistula, hemorrhage, and arterial thromboembolism. In particular, patients with liver cirrhosis (LC) show an increased risk of variceal bleeding. However, brain hemorrhage associated with the use of bevacizumab in patients with HCC and LC is extremely rare. We encountered two cases of brain hemorrhage in patients with HCC and LC who underwent treatment with atezolizumab and bevacizumab. One patient had no history of hypertension, while the other patient had hypertension that was well-controlled with medication and an unruptured brain aneurysm located on the right side of the anterior communicating artery. Both patients experienced brain hemorrhage after two treatment cycles of atezolizumab with bevacizumab. One patient died due to brain hemorrhage, while the other patient recovered from subarachnoid hemorrhage with successful coil embolization. This case report suggests that if a patient has any high-risk factors associated with brain hemorrhage, physicians should thoroughly consider alternative treatment options for advanced HCC, as brain hemorrhage could be fatal.

1 January 2026 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HPHyun Joon Park
Hyun Joon Park
JJJin Kyu Jung
Jin Kyu Jung
JNJeonghwan Noh
Jeonghwan Noh
YKYeonsu Kim
Yeonsu Kim
SLSang Uk Lee
Sang Uk Lee
KSKwang Il Seo
Kwang Il Seo
Park HJ, et al. J Korean Med Sci. 2026 May;41:e134. https://doi.org/10.3346/jkms.2026.41.e134